These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 15580148

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.
    Korzenik JR.
    Gastroenterol Clin North Am; 2004 Jun; 33(2):285-301, ix. PubMed ID: 15177539
    [Abstract] [Full Text] [Related]

  • 27. Anti TNF-alpha treatment for Crohn' disease: "ménage a trois".
    Danese S.
    Curr Drug Targets; 2010 Feb; 11(2):136-7. PubMed ID: 20214597
    [No Abstract] [Full Text] [Related]

  • 28. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A.
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [Abstract] [Full Text] [Related]

  • 29. Tumor necrosis factor inhibitors in psoriasis: an update.
    Kerdel FA, Strober BE.
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
    [Abstract] [Full Text] [Related]

  • 30. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
    van den Brande J, Hommes DW, Peppelenbosch MP.
    J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
    [Abstract] [Full Text] [Related]

  • 31. Anti-TNF antibodies for Crohn's disease--in pursuit of the perfect clinical trial.
    Lewis JD.
    N Engl J Med; 2007 Jul 19; 357(3):296-8. PubMed ID: 17634466
    [No Abstract] [Full Text] [Related]

  • 32. Mucosal healing and anti TNFs in IBD.
    van Assche G, Vermeire S, Rutgeerts P.
    Curr Drug Targets; 2010 Feb 19; 11(2):227-33. PubMed ID: 20210770
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
    Licastro F, Chiappelli M, Ianni M, Porcellini E.
    Int J Immunopathol Pharmacol; 2009 Feb 19; 22(3):567-72. PubMed ID: 19822073
    [Abstract] [Full Text] [Related]

  • 35. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD.
    J Crohns Colitis; 2014 Jun 19; 8(6):480-8. PubMed ID: 24268978
    [Abstract] [Full Text] [Related]

  • 36. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.
    Ophthalmology; 2014 Mar 19; 121(3):785-96.e3. PubMed ID: 24359625
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The classics in perspective.
    Panés J, Ghosh S.
    Gut; 2007 Sep 19; 56(9):1184-6. PubMed ID: 17698863
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870).
    Dinesen L, Travis S.
    Int J Nanomedicine; 2007 Sep 19; 2(1):39-47. PubMed ID: 17722511
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.